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Host response elicited by photodynamic therapy (PDT) of cancerous lesions is a critical contributor to the clinical outcome, and
complement system has emerged as its important element. Amplification of complement action was shown to improve tumour PDT
response. In search of a clinically relevant complement activator for use as a PDT adjuvant, this study focused on g-inulin and
examined its effects on PDT response of mouse tumours. Intralesional g-inulin (0.1mgmouse
 1) delivered immediately after PDT
rivaled zymosan (potent classical complement activator) in delaying the recurrence of B16BL6 melanomas. This effect of g-inulin was
further enhanced by IFN-g pretreatment. Tumour C3 protein levels, already elevated after individual PDT or g-inulin treatments,
increased much higher after their combination. With fibrosarcomas MCA205 and FsaR, adjuvant g-inulin proved highly effective in
reducing recurrence rates following PDT using four different photosensitisers (BPD, ce6, Photofrin, and mTHPC). At 3 days after
PDT plus g-inulin treatment, over 50% of cells found at the tumour site were CTLs engaged in killing specific targets via perforin–
granzyme pathway. This study demonstrates that g-inulin is highly effective PDT adjuvant and suggests that by amplifying the activation
of complement system, this agent potentiates the development of CTL-mediated immunity against PDT-treated tumours.
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Photodynamic therapy (PDT), in which the destruction of
cancerous lesions is achieved by the targeted site-localised
generation of reactive oxygen species formed by the transfer to
molecular oxygen of energy captured by the light excitation of
photosensitising drugs (Dougherty et al, 1998; Huang, 2005), has
not yet reached its full clinical potential. In addition to further
development of more potent photosensitising drugs and their
selective tumour localization, a promising approach appears in
exploiting the PDT-associated host response. Tumour PDT elicits a
strong host response orchestrated by the innate immune system
that culminates in the development of adaptive immunity against
the treated lesion, and renders an important contribution to the
therapy outcome (Henderson and Gollnick, 2003; Castano et al,
2006; Korbelik, 2006). It has recently become evident that
complement system is engaged at multiple levels in the execution
of this host response, including (i) initial recognition of
endogenous danger signals generated by tumour-localised insult
inflicted by PDT, (ii) incitement and propagation of the elicited
inflammatory response, (iii) efferocytosis (dead cell removal), and
(iv) tumour antigen presentation and promotion of adaptive
immune response recognising the PDT-treated tumour as its target
(Cecic and Korbelik, 2006; Cecic et al, 2006; Korbelik and Sun,
2006).
Supportive evidence of the importance of the contribution of the
activated complement system includes the decrease in cure rates of
PDT-treated tumours following blockage of complement activation
by the inhibitor FUT-175 (Korbelik, 2006), or specific inactivation
of complement anaphylatoxins C3a and C5a (Cecic et al, 2005). On
the other hand, enhancement of complement activation following
tumour PDT was shown to boost the curative outcome (Korbelik
et al, 2004). This has led to the idea to exploit the involvement of
complement system in PDT response by amplifying its activity
with adjuvant treatment for stimulating complement activation.
In initial studies that established the potential of such adjuvants
for increasing the effectiveness of tumour PDT, we used zymosan,
streptokinase, and urokinase (Korbelik et al, 2004). Zymosan
(particles from the cell wall of Saccharomyces cerevisiae)i sa
standard and potent complement activator but it is not safe for
clinical use (Volman et al, 2002), while streptokinase and
urokinase are clinically acceptable but are primarily acting as
anticoagulating agents (Ewald and Eisenberg, 1995; Oren et al,
1998). Hence, the present study evaluated g-inulin as the adjuvant
to tumour PDT because this neutral polyfructose derived from
storage carbohydrates of Compositae plant family is highly potent
in specific activation of the alternative pathway of complement
system and has established safety for human use (Frazer et al,
1999). Highly successful Phase I clinical trial with g-inulin as
adjuvant and hepatitis B surface antigen is just completed, with
no safety issues and good human activity (Petrovsky N et al,
unpublished data). The present study reports that g-inulin
treatment is highly effective in elevating PDT-mediated cures of
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smouse tumours and reveals that its action amplifies CTL activity
against PDT-treated tumours.
MATERIALS AND METHODS
Tumour models
Melanoma B16BL6 (Poste et al, 1980) and fibrosarcoma MCA205
(Barth et al, 1990) were grown in syngeneic C57BL/6 mice, and
fibrosarcoma FsaR (Volpe et al, 1985) in syngeneic C3H/HeN mice
using 6–8-week-old females. The mice were kept in sterile cages
housed in the animal facility of the British Columbia Cancer
Research Centre. All animal procedures were conducted according
to the approval from The Animal Ethics Committee of the
University of British Columbia and meet the standards required
by the UKCCR guidelines (Workman et al, 1998). Cohorts of
tumours for individual experiments were implanted from the same
tumour cell suspension by injecting 1–2 10
6 cellsmouse
 1
subcutaneously at the sacral region on the dorsal site. The
tumours were treated when their largest diameter reached 6–8mm
(around 8 days post implant).
c-Inulin
The g-inulin preparation was made from dahlia tubers as
endotoxin-free suspension of 1–2mm ovoids of insoluble form
of inulin, b-D-(2-1) polyfructofuranosyl a-D-glucose, in which an
unbranched chain of up to 100 fructose moieties is linked to a
single terminal glucose (Cooper and Carter, 1986a). The formula-
tion selects the high molecular weight form (up to 16000) of this
inert polysaccharide with the greatest potency for the activation
of alternative complement pathway by providing an optimised
surface that binds C3b while shielding it from inactivation by
factor H (Cooper, 1993). The treatments were performed by
intratumoural injection of 0.1mg (40ml) of g-inulin suspension
immediately after PDT light exposure. Controls involving the
intratumoural injection of the same volume of saline verified the
absence of injection volume-related unspecific effects.
Photodynamic therapy treatment
The photosensitisers used in this study were benzoporphyrin
derivative monoacid ring A (BPD or verteporfin, a lipid-
formulated photosensitiser provided by QLT, Inc., Vancouver,
BC, Canada), Photofrin (provided by Axcan Pharma, Inc., Mont-
Saint-Hilaire, Quebec, Canada), m-tetrahydroxyphenylchlorin
(mTHPC, received from Scotia Pharmaceuticals Ltd, Stirling,
UK), and chlorin e6 (ce6, Frontier Scientific, Inc., Logan, UT,
USA). They were injected intravenously at 24h (Photofrin,
mTHPC), 3h (BPD), or 2h (ce6) before photodynamic light
treatment.
The procedure and equipment used for photodynamic light
treatment was described in detail elsewhere (Cecic et al, 2005).
Briefly, light for superficial tumour illumination was generated by
a 150W QTH lamp-based high throughput source with integrated
ellipsoid reflector (Sciencetech Inc., London, Ontario, Canada)
using interference filters matching the absorption peaks of
individual photosensitisers. Delivered light fluence rate was 80–
90mWcm
 2 (power output measured by a light power metre
divided by the surface of the illuminated area encompassing the
treated tumour). During light treatment, mice were restrained
unanaesthetised in special holders designed to expose the sacral
region of their backs.
For zymosan treatment, particles derived from the cell wall of
S. cerevisiae (Z42500, Sigma Chemical Co., St Louis, MO, USA)
were suspended in PBS and injected intratumourally
(0.5mgmouse
 1,5 0 ml) immediately after PDT light treatment.
Mouse IFN-g (PeproTech Inc., Rocky Hill, NJ, USA) was
administered peritumourally (3 10
4Umouse
 1) at 24h before
PDT light treatment.
After therapy, mice were monitored for tumour growth and no
sign of palpable tumour at 90 days post treatment qualified as a
cure. The effect of adjuvants in the absence of PDT was tested by
following tumour growth rates determined by caliper measure-
ment of the lesion’s three orthogonal diameters. Saline only
controls were tested for all of the used agents and they verified the
absence of unspecific effects related to injections.
C3 enzyme-linked immunosorbent assay
Mice were killed and tumours excised at 2 or 6h after PDT and/or
g-inulin treatment. The content of complement C3 protein in
tumour tissue homogenates was determined using enzyme-linked
immunosorbent assay (ELISA) assay as previously described in full
detail (Cecic et al, 2005). Briefly, multiplate wells were coated with
goat F(ab’)2 fragment to mouse C3 (Cappel Laboratories, Durham,
NC, USA; 1:1000 dilution in PBS), and test samples were added
after blocking procedure for a 1.5h incubation at 371C, which
was followed by staining with HRP-conjugated goat anti-mouse
C3 (Cappel; 1:5000 dilution in PBS with 0.05% Tween-20 and 1%
normal goat serum). The mouse C3 for standard was isolated and
purified from the plasma of male DAB/2J (C5-deficient) mice.
Flow cytometry
Tumours excised at 3 days after g-inulin only treatment, control
untreated tumours, and tissue materials collected from the tumour
sites at 3 days after PDT and PDT plus g-inulin treatments (there
was no sign of tumour left at that time with these two treatment
groups) were subjected to standard enzymatic disaggregation
procedure (Korbelik, 1993). Single-cell suspensions obtained in
this way were stained with FITC-conjugated rat-anti-mouse
CD107a (sc-19992) and PE-conjugated rat anti-mouse CD8 (both
from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), plus
PerCP-Cy5.5-conjugated rat anti-mouse panleukocyte marker
CD45 (Pharmingen, BD Biosciences, Mississauga, Ontario,
Canada). In addition, FITC-conjugated rat anti-mouse IgG2a
(eBioscience Inc., San Diego, CA, USA) was used as isotype
control for CD107a. These samples were then analysed by three-
colour flow cytometry using the Coulter Epics Elite ESP (Coulter
Electronics, Hialeah, FL, USA), with 20000 cells included for each
test. The percentage of FITC-positive cells was determined in
populations gated as CD45
þCD8
þ.
Statistical analysis
Tumour response/cure results were statistically analysed using
Log-rank test. The differences between means of the data from
other experiments were statistically evaluated based on Mann–
Whitney test. Statistical differences were considered significant
when Po0.05.
RESULTS
c-Inulin as photodynamic therapy adjuvant with B16BL6
tumours
Mouse B16BL6 melanoma is one of the most PDT-resistant tumour
models. With the use of BPD as photosensitiser for PDT, an initial
ablation of subcutaneous tumours can be achieved within 1 day of
treatment, but this is followed by the recurrence of these lesions
within several days after treatment (Figure 1). Higher doses of
photosensitiser and light than used in our experiments are not
helpful because they are toxic to mice. However, improved PDT
responses of these tumours can be obtained by adjuvant
treatments with agents that specifically activate complement
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ssystem. A single intratumoural injection of the classical comple-
ment activator zymosan (0.5mgmouse
 1) given immediately after
PDT light treatment doubled the time for tumour recurrence, while
over three-fold increase in the recurrence time was observed with
g-inulin (0.1mgmouse
 1) applied in the same fashion (Figure 1).
Both agents were most effective when injected directly into the
tumour. Zymosan or g-inulin treatment without PDT showed no
detectable impact on tumour growth (not shown). No benefit was
found with increasing the g-inulin dose in conjunction with PDT
treatment to 0.2mg per mouse (Figure 1). A potential for further
enhancement of the effect of g-inulin as PDT adjuvant may be
found in adding IFN-g (a single peritumoural injection of 3 10
4
units per mouse at 24h before PDT light treatment) to the
treatment protocol. This IFN-g treatment, which by itself was not
effective in boosting PDT response, produced in the combination
with g-inulin on average over a four-fold prolongation in the post
PDT recurrence time of B16BL6 tumours (Figure 1). Moreover, one
among the eight tumours in this treatment groups was declared
cured (no sign of recurrence within 90 days) and was assigned the
recurrence time of 55 days in the calculation of the tumour
recurrence interval for this group. This was the main reason for the
large s.d. value for PDTþIFN-gþg-inulin group because of which
the difference with PDTþg-inulin has not reached the statistical
significance. It should be noted that B16BL6 melanomas exten-
sively metastasise from the primary site and form detectable lung
metastases within 2 weeks of initial implantation. In the course
of this study, there were in total 20 mice with tumour recurrence
times longer than 2 weeks after PDT plus g-inulin treatment and
none of them showed when killed signs of macroscopic lung
metastases. However, there were two cases of mice with no signs of
local tumour recurrence that had to be killed at 4–5 weeks post
therapy because they became affected with disseminated lung
deposits.
Tumour C3 levels
To verify the impact of g-inulin on complement activity in the
chosen experimental model, B16BL6 tumours were excised at
either 2 or 6h after treatment and samples prepared by
homogenisation of tumour tissue for ELISA-based determination
of the levels of C3 protein (key component of the complement
cascade). The results show that g-inulin treatment alone produced
a rise in tumour C3 levels at 2h after injection with a similar level
found 4h later (Figure 2). A comparable elevation in tumour C3
levels was detected at 2h after PDT only treatment, but an
additional rise was evident at 6h post PDT. Combining g-inulin
treatment with PDT showed no significant effect at 2h post
therapy, but produced significantly higher tumour C3 levels than
g-inulin or PDT alone (Po0.0286) at 6h post therapy.
Testing with various photosensitisers and tumour models
The efficacy of g-inulin as adjuvant to PDT was further examined
with different tumour models and photosensitisers. The treatment
of MCA205 fibrosarcomas with BPD-based PDT initially ablated all
the lesions, but this was in most cases followed by the recurrence
within the next 2 weeks and only 25% of mice remained tumour-
free at 90 days post therapy (Figure 3A). The group receiving g-
inulin (0.1mgmouse
 1 i.t.) immediately after photodynamic light
treatment showed a dramatic improvement evident as a decreased
tumour recurrence compared to the PDT only group and high
levels of cures. Similar results with the same tumour model were
obtained with two different photosensitisers, Photofrin and ce6; in
both cases, the chosen PDT only dose was in the moderate/halfway
cure range and the adjuvant g-inulin treatment increased the level
of tumour cures to fully or highly curative range by reducing the
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Figure 1 The effect of g-inulin and zymosan on PDT response of
B16BL6 tumours. Subcutaneously growing tumours were treated by PDT
(BPD 2.5mgml
 1 i.v. followed 3h later by 100Jcm
 2 of 690710nm light).
Zymosan (0.5mgmouse
 1) and g-inulin (0.1mgmouse
 1 except with one
treatment group that received 0.2mgmouse
 1) were administered by
intratumoural injection immediately after PDT light treatment, whereas
IFN-g (3 10
4Umouse
 1) was given peritumourally at 24h before PDT
light. All treated tumours showed initially a complete response followed by
the recurrence after time intervals that varied with different treatment
groups (presented in the ordinate as average time for tumour recurrence).
There was one cured tumour in PDTþIFN-gþg-inulin group (which
translates into 12.5% cure rate); for including it into the recurrence time
calculation, it was assigned time of 55 days. N¼8; bars are s.d. *Statistically
significant difference compared to PDT only group.
0
50
100
150
200
250
300
6 h post-treatment 2 h post-treatment
C
3
 
C
O
N
T
E
N
T
 
(

g
 
g
–
1
 
t
u
m
o
u
r
)
Nontreated
  -inulin
PDT
PDT +-inulin
Figure 2 Complement C3 levels in B16BL6 tumours following
treatment with PDT, g-inulin, or their combination. Tumours were excised
at either 2 or 6h after treatments performed as described for Figure 1
(0.1mgmouse
 1 for g-inulin), and samples from tumour tissue homo-
genates analysed by C3 ELISA. N¼4; bars are s.d. Values for all 2 and 6h
post-treatment groups were statistically different than with nontreated
group, and for PDT þ g-inulin group statistically higher than the other two
groups at the 6-h time point.
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srecurrence rate (Figure 3B and C). This effect was also confirmed
with a different syngeneic tumour model (subcutaneous FsaR
fibrosarcomas growing in C3H/HeN mice) and PDT based on
another photosensitiser (mTHPC) where g-inulin elevated the
tumour response rate from low to halfway curative range
(Figure 3D). Similarly as with other tumour models, g-inulin
treatment in the absence of PDT had no detectable effect on FsaR
tumours (not shown).
Detection of CD107a-positive CTL
An insight into the mechanisms of the observed adjuvant effect of
g-inulin is revealed by the flow cytometry-based detection at the
treated tumour site of cytotoxic T cells that have lysosomal-
associated membrane protein-1 (LAMP-1, CD107a antigen)
detectable on their surface (CD8
þCD107a
þ), which occurs when
these cells undergo degranulation (releasing granzyme B and
perforin) upon their contact with specific target cells (Burkett et al,
2005). Very few, if any, such cells were found in untreated MCA205
tumours. At 3 days after either intratumoural g-inulin injection
or ce6-PDT only treatment, small but significant increases in the
numbers of these cells were detectable at the treatment site. No
evidence of palpable tumour was detectable at this time point with
either PDT only or PDT plus g-inulin treatment. With the latter
group, the majority of cells collected from the treatment site were
leukocytes and stained as CD8 positive (Figure 4A). Further gating
of this CD8
þ population revealed a high intensity of CD107a
staining (in contrast to isotype control for this antibody) giving on
average over 50% degranulating cytotoxic T cells per total collected
cell population (Figure 4B).
DISCUSSION
Nonantigenic and nontoxic agent g-inulin is known as a specific
activator of alternative complement pathway in humans, mice, and
other mammalian species, and was demonstrated to be more
potent than strong standard complement activators zymosan and
killed S. aureus (Cooper and Carter, 1986a). Treatment of mice
with g-inulin was shown to result in deposition of complement
C3-fragments on the surface of macrophages, which enables these
antigen-presenting cells (APCs) to greatly increase their efficacy
in enhancing the proliferation of antigen-specific T cells (Kerekes
et al, 2001). Gamma-inulin is also a powerful adjuvant of the
antibody responses (Cooper and Steele, 1988; Silva et al, 2004).
Owing to these properties, there is also interest in g-inulin as
vaccine adjuvant, its safety for human use has been verified (Frazer
et al, 1999). It has also been known for some time that intralesional
g-inulin treatment elicits antitumour responses and it was
demonstrated that this results from the complement-activating
effect (Cooper and Carter, 1986b). Positive responses following
multiple treatment regimens were reported with mouse tumours
(B16 melanoma model), squamous cell carcinoma in sheep, equine
sarcoids, and spontaneous malignancies in dogs (Cooper and
Carter 1986b; Cooper, 1993).
Our recent related work has shown that complement component
C3 and other complement proteins accumulate in tumours treated
by PDT (Cecic and Korbelik, 2002; Cecic et al, 2005), and that
complement system recognises PDT-treated tumour cells as their
target (Cecic et al, 2006). Binding of complement proteins to
tumour antigens enhances their capture, processing, and presenta-
tion to T and B lymphocytes (Arvieux et al, 1988, Carroll, 2004),
and with PDT-generated cancer vaccines this property appears
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Figure 3 The effect of g-inulin on PDT response of MCA205 and FsaR fibrosarcomas. Subcutaneously growing MCA205 fibrosarcomas were treated with
(A) BPD-PDT (as described for Figure 1), (B) Photofrin-PDT (Photofrin 7.5mgkg
 1 i.v. followed 24h later by 150Jcm
 2 of 630710nm light), and (C)
ce6-PDT (ce6 5mgkg
 1 i.v. followed 2h later by 50Jcm
 2 of 665710nm light), while (D) FsaR fibrosarcomas were treated with mTHPC-PDT (mTHPC
0.1mgkg
 1 i.v. followed 24h later by 25Jcm
 2 of 655710nm light). The treatment with g-inulin (0.1mgmouse
 1) was as described for Figure 1. Following
treatment (that resulted in an initial complete response), the mice were monitored for signs of tumour regrowth; no sign of tumour at 90 days post therapy
qualified as a cure. N¼8. In all four cases, there was statistically significant difference between responses of PDTþg-inulin and PDT only groups.
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scritically important for securing ardent immune recognition of
targeted tumour and the development of effective antitumour
adaptive response (Korbelik and Sun, 2006).
Recurrence of tumours showing initially complete responses to
PDT treatment has a major impact on the success or failure with
this modality, and PDT-associated host response has become
recognised as a key determinant of the recurrence rate of these
tumours (Korbelik, 2006). The results of the present study
demonstrate that the adjuvant treatment with g-inulin is highly
effective in reducing the recurrence rate of various types of mouse
tumours following PDT mediated by different types of photo-
sensitisers, including tumour vasculature-concentrated BPD and
ce6, as well as tumour parenchyma-concentrated Photofrin and
mTHPC. The obtained findings suggest that combining g-inulin
treatment with PDT secures fully or highly curative results with
tumours that are not exceptionally resistant to PDT. Although in a
direct comparison with the potent complement activator zymosan,
using B16BL6 melanoma model, g-inulin has not statistically
proven significantly more effective in delaying the recurrence of
PDT-treated tumours, it produced on average over three-fold
increase in tumour recurrence time (compared to PDT only group)
while this increase with zymosan was only two-fold (Figure 1).
Moreover, curative threshold can be reached even with this highly
PDT-resistant model by including the administration of IFN-g
before PDT plus g-inulin treatment. The Th1 cytokine IFN-g
(originally called macrophage-activating factor) is well recognised
for its capacity to stimulate phagocytic activity of macrophages
and dendritic cells, and for augmenting the ability of these cells for
antigen processing and presentation by increased quantity and
diversity of peptides presented on their surface in the context
of MHC (Schroder et al, 2004). Thus, IFN-g treatment can boost
the activity of macrophages and/or dendritic cells in securing, in
conjunction with g-inulin potentiated complement activation,
immune recognition of PDT-treated tumours and augment
immune rejection of these lesions with resultant prevention of
tumour recurrence.
The assumed mechanism of action of g-inulin as adjuvant to
PDT, suggesting that reduced tumour recurrence rates are due
to an enhanced activation of adaptive immunity, implies that
increased numbers of cytotoxic T cells recognising cancer cells
from the PDT-treated tumour as their target should be engaged at
the treatment site. This was directly confirmed by the finding with
PDT plus g-inulin group that over 50% of cells at the tumour site at
3 days post PDT are CD107a-positive CD8 cells (Figure 4). These
CD8 cells could express the CD107a antigen on their surface only
after exocytosis of their granzyme and perforin-rich granules,
which occurs upon attacking their specific targets in an antigen-
specific manner (Betts et al, 2003).
Although detailed analysis of the impact of tumour-localised
g-inulin treatment on the formation of distant metastases was not
the objective of this study, evidence was collected suggesting that
this agent in conjunction with PDT attenuates metastatic spread of
B16BL6 melanoma and this supports the existence of a systemic
antitumour immune response developed after PDT plus g-inulin
treatment.
In summary, the present study demonstrates that the specific
potent complement activator g-inulin (nonantigenic natural
carbohydrate verified as safe for human use) is a highly efficient
adjuvant to tumour PDT with mouse tumour models. As its
adjuvant efficacy was documented with different tumour types,
including poorly immunogenic melanoma model, it can be
expected that g-inulin will work as adjuvant to PDT of human
cancers. The results suggest that by boosting the activation of
complement system, this agent potentiates the development of
cytotoxic T-cell-mediated immunity against the PDT-treated
tumour, which results in the abolishment or reduction in tumour
recurrence rates.
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